Verona Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Verona Pharma PLC
VRNA Stock  USD 106.69  0.30  0.28%   
Verona Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Verona Pharma's valuation are provided below:
Gross Profit
210.9 M
Profit Margin
(0.37)
Market Capitalization
9.1 B
Enterprise Value Revenue
40.5136
Revenue
221.7 M
We have found one hundred twenty available fundamental trend indicators for Verona Pharma PLC, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Verona Pharma PLC current market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 28.6 B. The current year's Enterprise Value is expected to grow to about 28.4 B

Verona Pharma Total Revenue

44.39 Million

Check Verona Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verona Pharma's main balance sheet or income statement drivers, such as Interest Expense of 24.7 M, Selling General Administrative of 157.2 M or Other Operating Expenses of 206.8 M, as well as many indicators such as Price To Sales Ratio of 97.85, Dividend Yield of 0.0 or PTB Ratio of 19.44. Verona financial statements analysis is a perfect complement when working with Verona Pharma Valuation or Volatility modules.
  
Build AI portfolio with Verona Stock
Check out the analysis of Verona Pharma Correlation against competitors.

Verona Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets498 M474.2 M144.4 M
Slightly volatile
Total Current Liabilities44.8 M42.7 M13.6 M
Slightly volatile
Total Stockholder Equity214.8 M204.6 M96.9 M
Slightly volatile
Accounts Payable11.8 M11.3 M3.2 M
Slightly volatile
Cash419.7 M399.8 M114.4 M
Slightly volatile
Non Current Assets Total21.7 M20.7 M7.9 M
Slightly volatile
Cash And Short Term Investments419.7 M399.8 M122.8 M
Slightly volatile
Net Receivables39.1 M37.3 M9.1 M
Slightly volatile
Common Stock Shares Outstanding85.6 M81.5 M41.9 M
Slightly volatile
Liabilities And Stockholders Equity498 M474.2 M144.4 M
Slightly volatile
Other Current Assets10.8 M10.3 M4.7 M
Slightly volatile
Other Stockholder Equity762.9 M726.5 M256.7 M
Slightly volatile
Total Liabilities283.2 M269.7 M47.5 M
Slightly volatile
Total Current Assets476.3 M453.6 M136.6 M
Slightly volatile
Common Stock45.5 M43.4 M16.5 M
Slightly volatile
Other Current Liabilities21.3 M20.3 M8.6 M
Slightly volatile
Property Plant And Equipment Net3.3 M3.2 M874.9 K
Slightly volatile
Good Will466 K490.5 K1.2 M
Slightly volatile
Property Plant And Equipment Gross3.3 M3.2 M793.8 K
Slightly volatile
Intangible Assets4.4 M4.2 M2.3 M
Slightly volatile
Net Tangible Assets277.6 M264.4 M99.7 M
Slightly volatile
Property Plant Equipment1.1 M1.1 M482.9 K
Slightly volatile
Capital Surpluse97.2 M136.7 M80.3 M
Slightly volatile
Net Invested Capital197.6 M324.9 M149.4 M
Slightly volatile
Net Working Capital431.4 M410.9 M165 M
Slightly volatile
Capital Stock32.3 M45 M18.2 M
Slightly volatile

Verona Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative157.2 M149.8 M27.3 M
Slightly volatile
Other Operating Expenses206.8 M196.9 M54.2 M
Slightly volatile
Total Operating Expenses204 M194.3 M53.8 M
Slightly volatile
Depreciation And Amortization1.1 M1.1 M370.9 K
Slightly volatile
Research Development46.8 M44.6 M25.6 M
Slightly volatile
Interest Income16 M15.3 M3 M
Slightly volatile
Reconciled Depreciation621.1 K1.1 M393.9 K
Slightly volatile
Selling And Marketing Expenses16.7 M17.4 M21.2 M
Slightly volatile

Verona Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow285.4 M271.8 M81.3 M
Slightly volatile
End Period Cash Flow419.7 M399.8 M114.4 M
Slightly volatile
Stock Based Compensation43.3 M41.2 M11.2 M
Slightly volatile
Depreciation1.1 M1.1 M344.6 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio97.851034 K
Very volatile
PTB Ratio19.4418.51134.4912
Slightly volatile
Days Sales Outstanding35137058.9 K
Very volatile
Book Value Per Share2.382.50875.0914
Slightly volatile
Invested Capital5 M5.7 M6.2 M
Slightly volatile
Average Payables1.2 M1.2 M1.1 M
Slightly volatile
Stock Based Compensation To Revenue1.071.12171
Very volatile
Capex To Depreciation0.520.54821.8275
Slightly volatile
PB Ratio19.4418.51134.4912
Slightly volatile
EV To Sales77681630.9 K
Very volatile
Inventory Turnover0.390.370.1906
Slightly volatile
Days Of Inventory On Hand9651 K2.2 K
Slightly volatile
Payables Turnover0.220.22920.4413
Very volatile
Sales General And Administrative To Revenue17.1718.07425
Very volatile
Research And Ddevelopement To Revenue1.151.211.7 K
Very volatile
Capex To Revenue0.0150.015817.5531
Very volatile
Cash Per Share3.794.90274.6642
Very volatile
Days Payables Outstanding1.3 K1.6 K1.5 K
Slightly volatile
Intangibles To Total Assets0.00110.00110.1605
Slightly volatile
Net Debt To EBITDA1.851.948511.0084
Slightly volatile
Current Ratio18.1710.62715.6988
Pretty Stable
Tangible Book Value Per Share4.922.5024.3881
Very volatile
Receivables Turnover1.281.31.7302
Slightly volatile
Shareholders Equity Per Share2.382.50875.0914
Slightly volatile
Debt To Equity0.630.59980.1146
Slightly volatile
Capex Per Share0.00680.00710.0524
Slightly volatile
Graham Net Net1.881.97633.719
Very volatile
Average Receivables3.4 M3.2 M2.3 M
Slightly volatile
Revenue Per Share0.490.470.2613
Slightly volatile
Interest Debt Per Share1.881.79360.3277
Slightly volatile
Debt To Assets0.270.25870.063
Slightly volatile
Graham Number0.170.190.2079
Slightly volatile
Operating Cycle1.3 K1.4 K59.5 K
Very volatile
Price Book Value Ratio19.4418.51134.4912
Slightly volatile
Days Of Payables Outstanding1.3 K1.6 K1.5 K
Slightly volatile
Company Equity Multiplier2.432.31841.3236
Slightly volatile
Long Term Debt To Capitalization0.390.37040.079
Slightly volatile
Total Debt To Capitalization0.390.37490.0826
Slightly volatile
Debt Equity Ratio0.630.59980.1146
Slightly volatile
Quick Ratio18.3810.480615.6966
Pretty Stable
Net Income Per E B T0.741.06310.9051
Very volatile
Cash Ratio15.399.366213.8968
Pretty Stable
Days Of Inventory Outstanding9651 K2.2 K
Slightly volatile
Days Of Sales Outstanding35137058.9 K
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.121.161.0357
Pretty Stable
Price To Book Ratio19.4418.51134.4912
Slightly volatile
Fixed Asset Turnover25.6715.4251.1233
Slightly volatile
Debt Ratio0.270.25870.063
Slightly volatile
Price Sales Ratio97.851034 K
Very volatile
Asset Turnover0.04270.08020.0478
Slightly volatile
Price Fair Value19.4418.51134.4912
Slightly volatile

Verona Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap28.6 B27.3 B11.3 B
Slightly volatile
Enterprise Value28.4 B27 B11.1 B
Slightly volatile

Verona Fundamental Market Drivers

Forward Price Earnings35.2113
Cash And Short Term Investments399.8 M

Verona Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Verona Pharma Financial Statements

Verona Pharma stakeholders use historical fundamental indicators, such as Verona Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Verona Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Verona Pharma's assets and liabilities are reflected in the revenues and expenses on Verona Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Verona Pharma PLC. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue687 K652.6 K
Total Revenue42.3 M44.4 M
Cost Of Revenue2.6 M2.7 M
Stock Based Compensation To Revenue 1.12  1.07 
Sales General And Administrative To Revenue 18.07  17.17 
Research And Ddevelopement To Revenue 1.21  1.15 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.47  0.49 
Ebit Per Revenue(3.29)(3.46)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
NOAHNoah Holdings
CIGCompanhia Energetica de
BBVABanco Bilbao Viscaya
When determining whether Verona Pharma PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verona Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verona Pharma Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verona Pharma Plc Stock:
How To Invest In Verona
Details
Is Verona Stock a good investment?
Details
What is Verona Pharma's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Verona Pharma Correlation against competitors.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.03)
Revenue Per Share
2.647
Return On Assets
(0.07)
Return On Equity
(0.36)
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY